Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DX6CWO
|
||||
| Drug Name |
1-(3-thiophen-3-yl-2,4-dihydro-indeno[1,2-c]pyrazole-5-carbonyl)-piperidine-3-carboxylic acid
|
||||
| Synonyms |
CHEMBL245734
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C21H19N3O3S
|
||||
| Canonical SMILES |
OC(=O)C1CCCN(C1)C(=O)c2cccc3c2Cc4c3n[nH]c4c5ccsc5
|
||||
| InChI |
InChI=1S/C21H19N3O3S/c25-20(24-7-2-3-12(10-24)21(26)27)15-5-1-4-14-16(15)9-17-18(22-23-19(14)17)13-6-8-28-11-13/h1,4-6,8,11-12H,2-3,7,9-10H2,(H,22,23)(H,26,27)
|
||||
| InChIKey |
WBRHCOIAJKWTPZ-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.